Boehringer Ingelheim plans PhIII chronic kidney disease trial for aldosterone-targeting drug after mid-stage success

03 Nov 2023

Phase 2

Boehringer Ingelheim’s aldosterone synthase inhibitor aldosterone synthase inhibitor reached the primary endpoint of a mid-phase chronic kidney disease trial in combination with its Eli Lilly-partnered drug Jardiance. Boehringer is now gearing up for a large registrational trial to start next year. Aldosterone synthase is an enzyme responsible for making aldosterone, and high levels of this hormone drive organ inflammation and fibrosis that can lead to conditions such as CKD and heart failure. The placebo-controlled Phase II trial studied multiple doses of Boehringer’s aldosterone synthase inhibitor aldosterone synthase inhibitor, dubbed BI 690517, with or without Jardiance in 714 CKD patients receiving stable background therapy.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Boehringer Ingelheim GmbHBoehringer AG

Indications

Chronic Kidney DiseasesInflammationFibrosis

[+1]

Targets

AldosteroneALDOS

Drugs

Aldosterone synthase inhibitors(Boehringer Ingelheim Corp)BI-690517Empagliflozin

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.